Key result
COVID-19 can cause multisystem inflammatory syndrome with myocardial damage that may last for months, manifesting as myocarditis, heart failure, or acute coronary syndrome.
Why the study?
The study was conducted to analyze current evidence regarding the etiology, pathogenesis, clinical manifestation, diagnosis, and treatment of COVID-19 associated myocarditis.
This review highlights the mechanisms, clinical manifestations, and diagnostic approaches for COVID-19-associated myocarditis, emphasizing the current lack of specific evidence-based treatments.
Answers are grounded in this paper and cite their sources.
May prompt extended cardiac monitoring after COVID-19; hypothesis-generating and requires validation in prospective cohorts.
The aim. To analyze current evidence about etiology, pathogenesis, clinical manifestation, diagnosis, and treatment of patients with COVID-19 associated myocarditis. Multisystem inflammatory syndrome is possible in COVID-19 including inflammatory damage to the myocardium, which may last over several months and worsen the disease outcome. Mechanisms of inflammatory cardiac damage include direct damage by SARS-CoV-2, massive release of cytokines, dysregulation of the renin-angiotensin system. All these factors can aggravate pre-existing overload of the right heart chambers in patients with multifocal pneumonia, thrombosis of coronary arteries and myocardial ischemia. Inflammation of the myocardium manifests with typical symptoms of myocarditis and pericarditis. It can be accompanied by heart failure with rapid decompensation, arrhythmia, acute coronary syndrome or even sudden death. Laboratory findings in COVID-19 associated myocarditis include high levels of CRP, BNP, NT-proBNP, and D-dimer. Transthoracic echocardiography allows for an assessment of the left ventricular dysfunction and diagnosis of a pericardial effusion. Heart MRI according to the Lake Louise Diagnostic Criteria is the most sensitive diagnostic method in acute myocarditis. Medical imaging is indicated only in cases when results obtained can potentially influence the patient management tactics and should be performed according to the shortest protocol due to high risks of virus transmission. Conclusions. ESC experts (2020) do not provide unanimous recommendations for the treatment of SARS-CoV-2 associated myocarditis, considering a lack of the evidence base. Patient management is limited to adequate treatment of heart failure, arrhythmia, acute coronary syndrome, and prevention of thrombotic complications. Ongoing studies are aiming to evaluate potential place of glucocorticoids, intravenous immunoglobulins, antibodies against IL-6 receptor, colchicine in the treatment of COVID-19.
No takes yet. Share an insight, caveat, or question.
Buheruk et al. (2021) conducted a review in COVID-19 associated myocarditis. COVID-19 can cause multisystem inflammatory syndrome with myocardial damage that may last for months, manifesting as myocarditis, heart failure, or acute coronary syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: